Evidence map›Paper›PMID 26380030›Full record

ArticleAmerican health & drug benefits

Trends in Medicare Part D Medication Therapy Management Eligibility Criteria.

Junling Wang, Ya-Chen Tina Shih, Yolanda Qin, Theo Young, Zachary Thomas, Christina A Spivey, David K Solomon, Marie Chisholm-Burns

Abstract read
In one paragraph

Article in American health & drug benefits. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Racial and ethnic disparities in the enrolment of medicare medication therapy management programs.Journal of pharmaceutical health services research : an official journal of the Royal Pharmaceutical Society of Great Britain · 2023
    Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Junling WangProfessor, Health Outcomes and Policy Research, Department of Clinical Pharmacy, University of Tennessee College of Pharmacy, Memphis.
Ya-Chen Tina ShihProfessor of Health Economics, and Chief, Section of Cancer Economics and Policy, Department of Health Services Research, University of Texas M.D. Anderson Cancer Center, Houston.
Yolanda QinStudent, Duke University, Durham, NC, and was a summer intern at the University of Tennessee, College of Pharmacy, Memphis, at the time of this study.
Theo YoungStudent, University of Mississippi School of Pharmacy, Jackson, and was a summer intern at the University of Tennessee College of Pharmacy, Memphis, at the time of this study.
Zachary ThomasStudent, University of Tennessee College of Pharmacy, Memphis.
Christina A SpiveyAssistant Professor, Department of Clinical Pharmacy, University of Tennessee College of Pharmacy, Memphis.
David K SolomonProfessor, Department of Clinical Pharmacy, University of Tennessee College of Pharmacy, Memphis.
Marie Chisholm-BurnsDean and Professor, University of Tennessee College of Pharmacy, Memphis.

Funding

Reducing Racial/Ethnic Disparities in Alzheimer's-Type Dementia with MTM ServicesR01AG040146 · NIA · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · PI Junling None Wang · 2011 to 2026
$3.7M
Resolving Racial/Ethnic Disparities Associated with Star Ratings among the ADRD PopulationR01AG049696 · NIA · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · PI WANG, JUNLING NONE · 2015 to 2022
$2.9M
NIA NIH HHS R01 AG040146NIA NIH HHS R01 AG049696
6 · The paper itself

Abstract

backgroundTo increase the enrollment rate of medication therapy management (MTM) programs in Medicare Part D plans, the US Centers for Medicare & Medicaid Services (CMS) lowered the allowable eligibility thresholds based on the number of chronic diseases and Part D drugs for Medicare Part D plans for 2010 and after. However, an increase in MTM enrollment rates has not been realized.

objectivesTo describe trends in MTM eligibility thresholds used by Medicare Part D plans and to identify patterns that may hinder enrollment in MTM programs.

methodsThis study analyzed data extracted from the Medicare Part D MTM Programs Fact Sheets (2008-2014). The annual percentages of utilizing each threshold value of the number of chronic diseases and Part D drugs, as well as other aspects of MTM enrollment practices, were analyzed among Medicare MTM programs that were established by Medicare Part D plans.

resultsFor 2010 and after, increased proportions of Medicare Part D plans set their eligibility thresholds at the maximum numbers allowable. For example, in 2008, 48.7% of Medicare Part D plans (N = 347:712) opened MTM enrollment to Medicare beneficiaries with only 2 chronic disease states (specific diseases varied between plans), whereas the other half restricted enrollment to patients with a minimum of 3 to 5 chronic disease states. After 2010, only approximately 20% of plans opened their MTM enrollment to patients with 2 chronic disease states, with the remaining 80% restricting enrollment to patients with 3 or more chronic diseases.

conclusionThe policy change by CMS for 2010 and after is associated with increased proportions of plans setting their MTM eligibility thresholds at the maximum numbers allowable. Changes to the eligibility thresholds by Medicare Part D plans might have acted as a barrier for increased MTM enrollment. Thus, CMS may need to identify alternative strategies to increase MTM enrollment in Medicare plans.

Indexed as

CMS guidanceMedicare Part D plansmedication therapy management (MTM) programMTM eligibility criteriaMTM enrollmentMTM thresholds

Identifiers

PMID26380030
PMCPMC4567055

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.